Thromboembolic events during treatment with thalidomide.

2. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9. 3. Shaldon S, Sherlock S. Portal hypertension in the myeloproliferative syndrome and the reticuloses. Am J Med. 1962;32:758-764. 4. Rossle M, Siegerstetter V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver. 1998;18:7389. 5. Sanyal AJ. The use and misuse of transjugular intrahepatic portasystemic shunts. Curr Gastroenterol Rep. 2000;2:61-71. 6. Freedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics. 1993; 13:1185-1210. 7. Cejna M, Peck-Radosavljevic M, Thurnher SA, Hittmair K, Schoder M, Lammer J. Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesis. Radiol. 2001;221:437-446. 8. Pereira A, Bruguera M, Cervantes F, Rozman C. Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases. Eur J Haematol. 1988;40:355-361. 9. Dubois A, Dauzat M, Pignodel C, et al. Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations. Hepatol. 1993;17:246-250. 10. Roux D, Merlio JP, Quinton A, Lamouliatte H, Balabaud C, Bioulac-Sage P. Agnogenic myeloid metaplasia, portal hypertension, and sinusoidal abnormalities. Gastroenterol. 1987;92:1067-1072.